Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–22.

Article  PubMed  Google Scholar 

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.

Article  CAS  PubMed  Google Scholar 

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. 2016;388(10055):2023–38.

Article  CAS  Google Scholar 

Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.

Article  CAS  PubMed  Google Scholar 

Wei K, Jiang P, Zhao J, Jin Y, Zhang R, Chang C, et al. Biomarkers to predict DMARDs efficacy and adverse effect in rheumatoid arthritis. Front Immunol. 2022;28:13.

Google Scholar 

Jin Y, Desai RJ, Liu J, Choi NK, Kim SC. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):159.

Article  PubMed  PubMed Central  Google Scholar 

Narváez J, Magallares B, DíazTorné C, Hernández MV, Reina D, Corominas H, et al. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum. 2016;45(4):386–90.

Article  PubMed  Google Scholar 

Pers YM, mentine Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Available from: https://academic.oup.com/rheumatology/article/53/1/76/1781300.

Cao M, Guo M, Wu DQ, Meng L. Pharmacogenomics of methotrexate: current status and future outlook. Curr Drug Metab. 2018;19(14):1182–7.

Article  CAS  PubMed  Google Scholar 

Salazar J, Moya P, Altés A, Díaz-Torné C, Casademont J, Cerdà-Gabaroi D, et al. Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics. 2014;15(8):1079–90.

Article  CAS  PubMed  Google Scholar 

Moya P, Salazar J, Arranz MJ, Díaz-Torné C, del Río E, Casademont J, et al. Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics. 2016;17(1):25–9.

Article  PubMed  Google Scholar 

Jekic B, Maksimovic N, Damnjanovic T. Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis. Pharmacogenomics. 2019;20(17):1235–45.

Article  CAS  PubMed  Google Scholar 

Márquez A, Ferreiro-Iglesias A, Dávila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E, et al. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. 2014. Available from: http://arthritis-research.com/content/16/2/R66.

Sode J, Vogel U, Bank S, Andersen PS, Lund Hetland M, Locht H, et al. Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis. 2015; Available from: www.lgcgenomics.com.

Bek S, Bojesen AB, Nielsen J v, Sode J, Bank S, Vogel U, et al. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Nature Publishing Group. 2017;17. Available from: http://permed2020.eu/.

Wysocki T, Paradowska-Gorycka A. Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy. 2022; Available from: https://doi.org/10.3390/ijms23042366.

Montes A, Perez-Pampin E, Joven B, Carreira P, Fernández-Nebro A, del Carmen OM, et al. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics. 2015;16(4):333–45.

Article  CAS  PubMed  Google Scholar 

Chen W, Xu H, Wang X, Gu J, Xiong H, Shi Y. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: a meta-analysis. Int Immunopharmacol. 2015;28(1):146–53.

Article  CAS  PubMed  Google Scholar 

Canet LM, Filipescu I, Cáliz R, Lupiañez CB, Canhão H, Escudero A, et al. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. Pharmacogenet Genomics. 2015;25(7):323–33.

Article  CAS  PubMed  Google Scholar 

Sainz L, Riera P, Moya P, Bernal S, Casademont J, Díaz-Torné C, et al. Role of IL6R genetic variants in predicting response to tocilizumab in patients with rheumatoid arthritis. Pharmaceutics. 2022;14(9):1942.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maldonado-Montoro M, Cañadas-Garre M, González-Utrilla A, Ángel C-H. Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. Pharmacogenomics J. 2018;18(1):167–72.

Article  CAS  PubMed  Google Scholar 

Maldonado-Montoro M, Cañadas-Garre M, González-Utrilla A, Plaza-Plaza JC, Calleja-Hernández M. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res. 2016;111:264–71.

Article  CAS  PubMed  Google Scholar 

Enevold C, Baslund B, Linde L, Josephsen NL, Tarp U, Lindegaard H, et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24(8):401–5.

Article  CAS  PubMed  Google Scholar 

Luxembourger C, Ruyssen-Witrand A, Ladhari C, Rittore C, Degboe Y, Maillefert JF, et al. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients. Pharmacogenomics J. 2019;19(4):368–74.

Article  CAS  PubMed  Google Scholar 

Wang J, Bansal AT, Martin M, Germer S, Benayed R, Essioux L, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J. 2013;13(3):235–41.

Article  PubMed  Google Scholar 

Sainz L, Riera P, Moya P, Bernal S, Casademont J, Díaz-Torné C, et al. Clinical value of IL6R gene variants as predictive biomarkers for toxicity to tocilizumab in patients with rheumatoid arthritis. J Pers Med. 2022;13(1):61.

Article  PubMed  PubMed Central  Google Scholar 

Huizinga TWJ, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73(9):1626–34.

Article  CAS  PubMed  Google Scholar 

Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–37.

Article  CAS  PubMed  Google Scholar 

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.

Article  PubMed  Google Scholar 

van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American college of rheumatology European league of associations for rheumatology. J Rheumatol. 1999;26(3):705–11.

PubMed  Google Scholar 

Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625–36.

Article  PubMed  Google Scholar 

U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed 10 Jan 2022.

Arguinano AA, Naderi E, Ndiaye NC, Stathopoulou M, Dadé S, Alizadeh B, et al. IL6R haplotype rs4845625*T/rs4537545*C is a risk factor for simultaneously high CRP. LDL and ApoB levels Genes Immun. 2017;18(3):163–9.

Article  CAS  PubMed  Google Scholar 

L. Phan, Y. Jin, H. Zhang, W. Qiang, E. Shekhtman, D. Shao, D. Revoe, R. Villamarin, E. Ivanchenko, M. Kimura, Z. Y. Wang, L. Hao, N. Sharopova, M. Bihan, A. Sturcke, M. Lee, N. Popova, W. Wu, C. Bastiani, M. Ward, J. B. Holmes, V. Lyoshin, K. Kaur, E. Moyer, M. Feolo, and B. L. Kattman. “ALFA: Allele Frequency Aggregator.” National Center for Biotechnology Information, U.S. National Library of Medicine. 2020. www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/.

Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, et al. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Semin Arthritis Rheum. 2018;47(6):757–64.

Article  CAS  PubMed  Google Scholar 

Ferreira RC, Freitag DF, Cutler AJ, Howson JMM, Rainbow DB, Smyth DJ, et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 2013;9(4):e1003444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah T, Zabaneh D, Gaunt T, Swerdlow DI, Shah S, Talmud PJ, et al. Gene-centric analysis identifies variants associated with interleukin-6 levels and shared pathways with other inflammation markers. Circ Cardiovasc Genet. 2013;6(2):163–70.

Article  CAS  PubMed  Google Scholar 

Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43–52.

Article  CAS  PubMed  Google Scholar 

Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, et al. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences Article. 2019; Available from: www.mdpi.com/journal/ijms. Cited 13 Oct 2022.

Lukas C, Redondin M, Pane I, Soubrier M, Houvenagel E, Sibilia J, et al. Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry. Clin Exp Rheumatol. 2021;39(3):501–7.

Article  PubMed  Google Scholar 

Castagné B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PLoS ONE. 2019;14(8):e0220178.